1-N-[(1S,2S)-3-(3,5-difluorophenyl)-1-(4-ethoxypyridin-2-yl)-1-hydroxypropan-2-yl]-5-methyl-3-N,3-N-dipropylbenzene-1,3-dicarboxamide | 845973-11-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-N-[(1S,2S)-3-(3,5-difluorophenyl)-1-(4-ethoxypyridin-2-yl)-1-hydroxypropan-2-yl]-5-methyl-3-N,3-N-dipropylbenzene-1,3-dicarboxamide
• CAS: 845973-11-7
• 化学式: C₃₁H₃₇F₂N₃O₄
• 分子量: 553.649
• InChiKey: SFPNOSMELZRCKQ-URLMMPGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-N-[(1S,2S)-3-(3,5-difluorophenyl)-1-(4-ethoxypyridin-2-yl)-1-hydroxypropan-2-yl]-5-methyl-3-N,3-N-dipropylbenzene-1,3-dicarboxamide 在 platinum(IV) oxide 、 氢气 、 溶剂黄146 作用下， 反应 2.0h， 以29%的产率得到
  参考文献：
  名称：

  [EN] CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT
  [FR] INHIBITEURS BACE-1 AMINES CYCLIQUES A SUBSTITUANT BENZAMIDE

  摘要：

  公开号：

  WO2005016876A3
• 作为产物：
  描述：

  3-(二丙基氨基甲酰基)-5-甲基苯甲酸 、 (1S,2S)-2-amino-3-(3,5-difluorophenyl)-1-(4-ethoxypyridin-2-yl)propan-1-ol 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以63%的产率得到1-N-[(1S,2S)-3-(3,5-difluorophenyl)-1-(4-ethoxypyridin-2-yl)-1-hydroxypropan-2-yl]-5-methyl-3-N,3-N-dipropylbenzene-1,3-dicarboxamide
  参考文献：
  名称：

  Potent pyrrolidine- and piperidine-based BACE-1 inhibitors

  摘要：

  Based on lead compound I identified from the patent literature, we developed novel patentable BACE-1 inhibitors by introducing a cyclic amine scaffold. Extensive SAR studies on both pyrrolidines and piperidines ultimately led to inhibitor 2f, one of the most potent inhibitors synthesized to date. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.116

文献信息

• CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT
  申请人：Cumming Jared N.

  公开号：US20100152138A1

  公开（公告）日：2010-06-17

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

  本发明揭示了式I的化合物，或其药学上可接受的盐或溶剂，其中R1是R是—C（O）—N（R27）（R28）或，其余变量如规范中所定义。本发明还揭示了包括式I化合物的药物组成物。本发明还揭示了治疗认知或神经退行性疾病，如阿尔茨海默病的方法。本发明还揭示了包括式I化合物的药物组成物和治疗认知或神经退行性疾病的方法，其中该组成物与β-分泌酶抑制剂（非式I的）、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天门冬氨酸受体拮抗剂、胆碱酯酶抑制剂或抗淀粉样蛋白抗体结合使用。
• CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT
  申请人：Pharmacopeia Drug Discovery, Inc.

  公开号：US20140128361A1

  公开（公告）日：2014-05-08

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

  本发明涉及以下公式的化合物，或其药学上可接受的盐或溶剂： 其中，R1是R为—C（O）—N（R27）（R28）或 其余变量如规范中所定义。 本发明还涉及包括公式I化合物的制药组合物。 本发明还涉及治疗认知或神经退行性疾病（如阿尔茨海默病）的方法。 本发明还涉及包括公式I化合物与β-分泌酶抑制剂、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天门冬氨酸受体拮抗剂、胆碱酯酶抑制剂或抗淀粉样蛋白抗体组合的治疗认知或神经退行性疾病的制药组合物和方法。
• US7662816B2
  申请人：——

  公开号：US7662816B2

  公开（公告）日：2010-02-16
• US8278334B2
  申请人：——

  公开号：US8278334B2

  公开（公告）日：2012-10-02
• US8623867B2
  申请人：——

  公开号：US8623867B2

  公开（公告）日：2014-01-07